GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI
Frontiers in EndocrinologyBackgroundGlucagon-like peptide-1 receptor agonist(GLP-1RA) is commonly used in patients with cardiovascular disease due to its significant improvement in the prognosis of atherosclerotic cardiovascular disease (ASCVD).
Ling Xu, Dan Zhu
exaly +4 more sources
GLP-1RA and the possible skin aging [PDF]
EndocrineAbstract “Ozempic face” and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic inflammation and possibly promote skin health.
Stavroula A Paschou +2 more
exaly +5 more sources
Frontiers in Pharmacology, 2022 Background: GLP-1 receptor agonists (GLP-1RA) have demonstrated cardiovascular benefits, but the relationship between GLP-1RA and tumors is controversial.
Yuhuan Lv, Meng Yu, Mei Mei
exaly +3 more sources
GLP-1RA Medications Significantly Reduce Fracture Risk in the Diabetic Foot and Ankle Patient Population [PDF]
Foot & Ankle OrthopaedicsResearch Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Diabetes mellitus (DM) is associated with an elevated risk for sustaining a fracture, driven by both direct and indirect ...
Samantha Olson BS +4 more
doaj +2 more sources
Kidney Medicine, 2023 Rationale & Objective: Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited.
Julie Z. Zhao +3 more
doaj +1 more source
Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany. [PDF]
PLoS ONE, 2016 AIMS:To investigate real-world clinical and patient-related variables associated with initiating GLP-1 receptor agonist (GLP-1RA) treatment relative to initiation of other glucose-lowering therapies in type 2 diabetes (T2D) patients of primary care in ...
Qing Qiao +3 more
doaj +1 more source
Metabolites, 2022 Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits.
Irene Caruso +6 more
doaj +1 more source
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study [PDF]
Diabetes & Metabolism Journal, 2023 We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes ...
Minyoung Kim +7 more
doaj +1 more source
Therapeutic Advances in Endocrinology and Metabolism, 2023 Background: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. Objectives: To determine, from the patients’ perspective, the reasons for initiation of glucagon-like ...
Khary Edwards +4 more
doaj +1 more source
GLP ‐ 1RA and Liver Fibrosis Progression in MASLD and Type 2 Diabetes: Target Trial Emulation Using Propensity Score Matching [PDF]
Liver InternationalJonggi Choi +2 more
exaly +2 more sources